Bafna Pharmaceuticals Limited (BAFNAPH) Stock Price & Analysis

0 Followers

BAFNAPH Stock Chart & Stats

₹494.15₹9.65(1.99%)

At close: Nov 12 3:30 PM GMT+5:30

Day’s Range: INR 494.15 - INR 494.15
52-Week Range: INR 95.00 - INR 494.15
Previous Close: INR 484.50
Volume: N/A
Average Volume (3M): 7,140
Market Cap: INR 11.28B
Enterprise Value: INR 9.28B
Total Cash (Recent Filing): INR 20.25M
Total Debt (Recent Filing): INR 0
Price to Earnings (P/E): 146.6
Beta: 0.60
Next Earnings: Feb 11, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Sep 19, 2013
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Long-term Revenue Growth

Strong multi-year revenue expansion indicates that Bafna Pharmaceuticals has increased its business scale across finished formulations and therapeutic categories. Continued topline growth can broaden operating reach, support reinvestment in the portfolio, and provide a durable base for future earnings development.

Reasonably Sound Balance Sheet

A growing equity base and moderate leverage provide financial support for ongoing operations and investment. Although debt has risen, the balance sheet still offers a meaningful buffer against business volatility and gives the company more capacity to fund growth than a highly leveraged structure would.

Recent Earnings Recovery

The sharp 2026 net income rebound shows that profitability can recover after periods of pressure, supporting the resilience of the underlying business model. If maintained, improved earnings can strengthen internal funding capacity and help offset earlier margin deterioration over coming quarters.

Bears Say

Persistent Negative Free Cash Flow

Negative free cash flow in most reported years indicates that reinvestment and/or working-capital demands are absorbing cash despite reported profits. Persistent cash shortfalls reduce financial flexibility, limit internally funded growth, and could increase reliance on external funding if the pattern continues.

Uneven Margin Performance

Material margin compression after the strong 2022–2023 period shows that earnings quality has not been consistently stable. Uneven profitability makes future earnings less predictable, can weaken the cash conversion of revenue growth, and may constrain investment if operating pressure returns.

Rising Debt Trend

Although leverage remains moderate, the recent increase in debt adds a developing pressure to the financial structure. Higher borrowings can raise future financing obligations and reduce flexibility during weaker operating periods, making sustained cash generation increasingly important for balance-sheet resilience.

Bafna Pharmaceuticals Limited News

Bafna Pharmaceuticals Approves Unaudited Results for Quarter and Half Year Ended September 2026

An announcement from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited manufactures pharmaceutical formulations, which the company identifies as its only operating segment under Ind AS

1d ago

Bafna Pharmaceuticals Shuts Trading Window Ahead of Q2 FY27 Results

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has issued an announcement. Bafna Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line

1M ago

Bafna Pharmaceuticals Files SEBI Demat Compliance Certificate for June Quarter

An update from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited, a Chennai-based drug maker listed on Indian exchanges, manufactures pharmaceuticals from its facilities in Tamil

4M ago

Exchange Seeks Clarification from Bafna Pharmaceuticals on Sharp Share Price Move

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) just unveiled an update. Significant price movement in the shares of Bafna Pharmaceuticals Limited has prompted the stock exchange to seek updated, relevant information

7M ago

Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results

An announcement from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals has announced the closure of its trading window for designated persons and their immediate relatives from

7M ago

Bafna Pharmaceuticals Files SEBI Dematerialisation Compliance Certificate for Q3 FY2025

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted to the stock exchanges a compliance certificate for the quarter ended 31 December 2025 under

10M ago

Bafna Pharmaceuticals Completes Sale of Chennai Manufacturing Unit

An update from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited has completed the sale of its manufacturing unit located in Madhavaram, Chennai, to Navron Pharma

1y ago

Bafna Pharmaceuticals Submits Annual SEBI Disclosure

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted its annual disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations,

1y ago

Bafna Pharmaceuticals Announces Board and Committee Restructuring

The latest update is out from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ). Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24,

1y ago

Bafna Pharmaceuticals Announces Board and Committee Restructuring

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an announcement. Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This

1y ago

BAFNAPH FAQ

What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?

Bafna Pharmaceuticals Limited lowest stock price was ₹95.00 and its highest was ₹494.15 in the past 12 months.

What is Bafna Pharmaceuticals Limited’s market cap?

Bafna Pharmaceuticals Limited’s market cap is ₹11.28B.

When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Bafna Pharmaceuticals Limited’s earnings last quarter?

Bafna Pharmaceuticals Limited released its earnings results on Nov 11, 2026. The company reported ₹2.895 earnings per share for the quarter.

Is Bafna Pharmaceuticals Limited overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Bafna Pharmaceuticals Limited pay dividends?

Bafna Pharmaceuticals Limited pays a dividend of ₹0.6 which represents an annual dividend yield of ―. See more information on Bafna Pharmaceuticals Limited dividends here

What is Bafna Pharmaceuticals Limited’s EPS estimate?

Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bafna Pharmaceuticals Limited have?

Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.

What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?

Bafna Pharmaceuticals Limited reported an EPS of ₹2.895 in its last earnings report. Following the earnings report the stock price went up 1.572%.

Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:BAFNAPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description